Drug Profile
Research programme: alpha-II adrenergic receptor agonists - AbbVie
Alternative Names: Alpha-II agonist - AbbVieLatest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Developer AbbVie
- Class
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glaucoma in USA
- 12 Jul 2012 Preclinical trials in Glaucoma in USA (unspecified route)